Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications
Authors:
- Romano DanesiRDRomano Danesi
- Joseph P. BoniJBJoseph P. Boni
- Alain RavaudARAlain Ravaud
- 1 November 2013
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (7) , 784-792
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Novartis
- Pfizer
- Roche
This publication has 52 references indexed in Scilit:
- Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinomaCancer, 2009
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature reviewCancer Treatment Reviews, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- The follow‐up management of non‐metastatic renal cell carcinoma: definition of a surveillance protocolBJU International, 2006
- Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor ProteinJournal of Biological Chemistry, 2000